Pharmaceutical News

RSS

Biogen Idec announces acceptance of marketing applications for review of PLEGRIDY

Today Biogen Idec announced that U.S. and EU regulatory authorities have accepted the marketing applications for the review of PLEGRIDY (peginterferon beta-1a), the company's pegylated subcutaneous injectable candidate for relapsing forms of multiple sclerosis.

19 Jul 2013

Tianyin Pharmaceutical provides further updates on Gingko Mihuan Oral Liquid

Tianyin Pharmaceutical Co., Inc., a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine, branded generics and active pharmaceutical ingredients today provided further updates on the business development of its flagship product: Gingko Mihuan Oral Liquid with the SFDA approval number: H20013079.

19 Jul 2013

Teduglutide offers relief for patients with short-bowel syndrome

A new drug, teduglutide, offers significant relief for patients with short-bowel syndrome intestinal failure who are reliant on intravenous nutrition, according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.

19 Jul 2013

Study supports topiramate as promising medication to treat addiction

The drug topiramate, typically used to treat epilepsy and more recently weight loss, may also help people addicted to both cocaine and alcohol use less cocaine, particularly heavy users, researchers in the department of Psychiatry at Penn Medicine report in a new study published in Drug and Alcohol Dependence.

19 Jul 2013

American Crystallographic Association analysis may help researchers design vaccine against HIV/AIDS

Designing an effective HIV/AIDS vaccine is something of a paradox: a good vaccine would be safe and look enough like HIV to kick-start the immune system into neutralizing the virus - but the problem is that this is exactly what the human immune system has trouble doing even when it's exposed to the real thing.

19 Jul 2013

Oxytocin may not improve symptoms of children with autism, study finds

The so-called trust hormone, oxytocin, may not improve the symptoms of children with autism, a large study led by researchers at the University of New South Wales has found.

19 Jul 2013

New data identifies specific cellular pathways by which RNS60 impacts Alzheimer's Disease

On Wednesday Revalesio Corporation presented new data at the Alzheimer's Association International Conference that identifies the specific cellular pathways by which Revalesio's lead investigational product, RNS60, impacts Alzheimer's Disease. This research, conducted in partnership with Rush University Medical Center, investigates a new category of therapeutics using Revalesio's novel nanotechnology platform.

19 Jul 2013

Metabolomics tools predict who can benefit from treatment with certain antidepressants

Duke Medicine researchers have identified biochemical changes in people taking antidepressants - but only in those whose depression improves. These changes occur in a neurotransmitter pathway that is connected to the pineal gland, the part of the endocrine system that controls the sleep cycle, suggesting an added link between sleep, depression and treatment outcomes.

19 Jul 2013

Nanotechnology drug kills brain-tumor cells and retards growth of tumor blood vessels

An experimental drug in early development for aggressive brain tumors can cross the blood-brain tumor barrier and kill tumor cells and block the growth of tumor blood vessels, according to a study led by researchers at the Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James).

19 Jul 2013

Idera Pharmaceuticals receives patent related to IMO-8400

Idera Pharmaceuticals, Inc. today announced that the United States Patent and Trademark Office has issued to Idera patent number 8,486,908, providing both composition of matter and method of use protection for IMO-8400.

19 Jul 2013

FDA grants orphan drug designation to ARMAGEN's AGT-182 for treatment of Hunter syndrome

ARMAGEN announced today that the U.S. Food and Drug Administration has granted orphan drug designation to its lead product AGT-182 for the treatment of mucopolysaccharidosis type II (also known as Hunter syndrome or MPS II).

19 Jul 2013

Par Pharmaceutical receives final ANDA approval for generic version of Trilipix

Par Pharmaceutical Companies, Inc. today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for fenofibric acid EQ 45 mg and EQ 135 mg delayed-release capsules.

19 Jul 2013

Bausch + Lomb obtains option to license MIM-D3 for treatment of dry eye syndrome

Bausch + Lomb, the global eye health company, and Mimetogen Pharmaceuticals Inc. today announced that Bausch + Lomb has acquired an option to license an investigational compound currently in Phase 2 development for the treatment of dry eye syndrome, a condition that affects millions of people worldwide.

19 Jul 2013

Boys more likely to receive HPV4 vaccine if their mothers receive flu shots, study finds

Boys are more likely to receive the quadrivalent human papillomavirus vaccine if their mothers receive flu shots or Pap screenings, according to a Kaiser Permanente study published in the American Journal of Public Health.

19 Jul 2013

Ensemble Therapeutics announces initiation of drug discovery collaboration with Alexion subsidiary

Ensemble Therapeutics, a biotechnology company developing Ensemblins, a novel class of small molecule therapeutics with the potential to modulate targets typically addressed by biologics, today announced the initiation of a drug discovery collaboration with a subsidiary of Alexion Pharmaceuticals, Inc., the global biopharmaceutical company focused on developing and commercializing life-transforming therapies for patients with life-threatening, ultra-rare disorders.

18 Jul 2013

Study brings new hope for patients with metastatic prostate cancer

A study of a new radiotherapeutic drug published this week in the New England Journal of Medicine brings fresh hope for a particular group of cancer patients that otherwise suffer and ultimately die from the disease -- those with prostate cancer that has spread to their bones and has failed to be controlled by hormone deprivation drugs.

18 Jul 2013

Quest Diagnostics completes sale of ibrutinib commercialization rights to Royalty Pharma

Quest Diagnostics Incorporated, the world's leading provider of diagnostic information services, announced today that it has completed the sale of its rights to royalties from commercialization of the drug candidate ibrutinib to Royalty Pharma, the industry leader in acquiring royalty interests in marketed and late stage biopharmaceutical products, for $485 million in cash.

From Quest Diagnostics 18 Jul 2013

Pharmaceutical News

Biogen Idec announces acceptance of marketing applications for review of PLEGRIDY

Tianyin Pharmaceutical provides further updates on Gingko Mihuan Oral Liquid

Teduglutide offers relief for patients with short-bowel syndrome

Study supports topiramate as promising medication to treat addiction

American Crystallographic Association analysis may help researchers design vaccine against HIV/AIDS

Oxytocin may not improve symptoms of children with autism, study finds

New data identifies specific cellular pathways by which RNS60 impacts Alzheimer's Disease

Metabolomics tools predict who can benefit from treatment with certain antidepressants

Nanotechnology drug kills brain-tumor cells and retards growth of tumor blood vessels

Idera Pharmaceuticals receives patent related to IMO-8400

FDA grants orphan drug designation to ARMAGEN's AGT-182 for treatment of Hunter syndrome

Par Pharmaceutical receives final ANDA approval for generic version of Trilipix

Bausch + Lomb obtains option to license MIM-D3 for treatment of dry eye syndrome

Boys more likely to receive HPV4 vaccine if their mothers receive flu shots, study finds

Ensemble Therapeutics announces initiation of drug discovery collaboration with Alexion subsidiary

Study brings new hope for patients with metastatic prostate cancer

Quest Diagnostics completes sale of ibrutinib commercialization rights to Royalty Pharma

Transition Therapeutics' ELND005 receives Fast Track Designation from FDA

TSRI scientists study 3-D structure of glucagon receptor for treatment of diabetes

Children exposed to AEDs in womb at risk of early development issues: Study

Advancing Motor Neuron Disease Diagnosis with Non-Invasive Ultrasound and AI

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

Latest News